To avoid the influence of non-tumour-originating AFP fluctuations (ie, those associated with hepatitis activity), we only assessed AFP response in patients with baseline AFP levels above 200 ng ml−1 (Liaw et al, 1986; Chen et al, 2009) and received treatments for at least 8 weeks. This evidence concerns the gene AFP and neoplasm.